common/抗癌药

CROSS-REFERENCE TO RELATED APPLICATION This application is a national stage of the international application PCT/FR03/00970, filed March 27, 2003, which claims benefit of the application FR 02/03888, filed Mar. 28, 2002. The present invention relates to peptides representing shared epitopes of tumor

FIELD OF THE INVENTION The present invention generally relates to the field of oncology, and particularly to the regulation of growth factors that stimulate the proliferation of cancerous cells and those that may be over-expressed, such as receptors, in cancerous cells. BACKGROUND OF THE

TECHNICAL FIELD This invention relates to C-glycosides produced by microorganisms, and an unglycosidated product thereof. These C-glycosides have a growth-inhibiting activity, for example, against tumor cells. BACKGROUND ART A large number of compounds have been proposed as antibiotics produced by

FIELD OF THE INVENTION The invention relates to the pharmaceutical field, concretely to the combined use of 2 active principles, pterostilbene and quercetin, in the manufacture of medicinal products that can be used for cancer treatment. STATE OF THE ART Various phenolic compounds, including

BACKGROUND OF THE INVENTION Field of the Invention This invention relates generally to treatment of solid cancers. More particularly, the invention relates to a synchrotron energy control system of a multi-axis and/or multi-field charged particle cancer therapy method and apparatus used for cancer

CROSS REFERENCE TO RELATED APPLICATIONS This application is a National Stage of International Application No. PCT/KR2013/004297 filed May 15, 2013, claiming priority based on Korean Patent Application No. 10-2013-0049297 filed on May 2, 2013, the contents of all of which are incorporated herein by

TECHNICAL FIELD This invention provides targeting-enhanced anticancer nanoparticles and preparation methods for the same. BACKGROUND ART Cancer is the most devastating disease to modern society because there are no effective treatments that do not incur side effects. Although many treatments are

FIELD OF THE INVENTION This invention is concerned with agents for the treatment of primary, metastatic and residual cancer in mammals (including humans) by inducing the immune system of the mammal or human afflicted with cancer to mount an attack against the tumour lesion. In particular, the

This application is a 371 of PCT/GB99/04129 filed on Dec. 9, 1999, which is hereby incorporated by reference. FIELD OF THE INVENTION This invention is concerned with agents for the treatment of primary, metastatic and residual cancer in mammals (including humans) by inducing the immune system of the

FIELD OF INVENTION The present invention relates to a method for treating cancer using an anti-cancer compound. More particularly, said anti-cancer compound is an anti-cervical-cancer compound. The present invention has a specific application in treating human cervical cancer. BACKGROUND OF

REFERENCE TO SEQUENCE LISTING The attached paper copy of the Sequence Listing for this application is identical to the Sequence Listing in computer readable form found on the accompanying computer disk, as required by 37 CFR 1.821(c), both of which are hereby incorporated by reference in their

SUMMARY OF THE INVENTION This invention relates to a new group of antibiotics, the A52688 complex. The A52688 complex contains at least ten factors, one of which is an analog of tuberin. The nine new A52688 factors (A, C, D, E, F, G, H, J and K) have the structures shown in formulas 1 through

TECHNICAL FIELD The present invention relates to antibiotics, anti-inflammatory agents, anti-hyperlipidemia agents, anti-diabetes agents and anticancer agents, manufactured using an old platycodon extract, based on various pharmacological effects of 20-year (or older) old platycodon produced in

FIELD OF INVENTION The present invention relates to the field of medicine. More specifically, the present invention relates to Temozolomide-8-carboxylate derivatives, method for preparing it, compositions comprising them and the use of the derivatives and compositions in the manufacture of a

BACKGROUND OF THE INVENTION Didemnin compounds were first reported by Rinehart et al. as isolates from the Caribbean tunicate Trididemnum solidum in 1981. These cyclic depsipeptides possess a variety of biological activities including in vitro and in vivo antiviral, antitumor, and immunosuppressive